Regarding the variation of PD-L1s during treatment, So Yeon Oh et al. analyzed pre- and post-treatment sPD-L1 levels in 67 patients with NSCLC, melanoma, small cell lung cancer (SCLC), urothelial carcinoma, and other cancers. Here, SPDL1 is linked to non-small cell lung carcinoma.